secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001104659-24-023665
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio and uBriGene withdraw and re-file CFIUS notice; new 45-day review period begins Feb 13
--------------------------------------------------------------------------------

- On Feb 12, 2024, CFIUS granted request to withdraw and re-file the joint voluntary notice for the transaction.
- New 45-day review period started Feb 13, 2024, concluding no later than March 28, 2024.
- If CFIUS does not conclude by March 28, the proceeding will transition to a second 45-day investigation phase.
- The CFIUS review relates to Mustang's sale of its Worcester cell processing facility and associated assets to uBriGene.
- CFIUS clearance was not a condition to closing the transaction, but is being pursued voluntarily.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000110465924023665/0001104659-24-023665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000110465924023665/tm246262d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-023665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer